FREMONT, Calif.–WaferGen Bio-systems, Inc. (OTCBB: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, announced that on Friday, March 27, it filed with the Securities and Exchange Commission its Annual Report on Form 10-K for the fiscal year ended December 31, 2008. Complete financial results for our 2008 fiscal year are contained in the 10-K, which can be accessed at www.sec.gov. The following summary of key accomplishments in 2008 and milestones for 2009 provides additional information about the Comnpany’s achievements and goals.

Corporate Development Highlights

Milestone Triggers Second $1 Million Investment from MTDC – Pursuant to the agreement announced in May of 2008 with the Malaysian Technology Development Corporation, due to achieving certain agreed-upon milestones WaferGen Biosystems (M) Sdn. Bdh., a Malaysian wholly owned subsidiary of WaferGen, has received the second $1 million investment in exchange for additional redeemable convertible preferred shares of the subsidiary.

Research Collaboration with UTSW – Announced the signing of a research collaboration with the University of Texas Southwestern Medical Center for the SmartChip™ Real-Time PCR System. Under terms of the collaboration, UT Southwestern will conduct novel research projects using the SmartChip™ Real-Time PCR System in order to identify and validate gene expression biomarkers related to wound healing. Additionally, researchers will aim to examine the impact the identified biomarkers have on patients’ response to treatment.

$3 Million NIH Grant – Announced that the National Institutes of Health (NIH) has awarded a team of researchers at the University of Pittsburgh an approximately $3 million grant to conduct novel gene expression research in the area of lung disease using WaferGen’s SmartChip™ Real-Time PCR System. NIH-funded research will include the development and application of the PulmoSmartChip™, a custom designed SmartChip™ molecular phenotyping assay for chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Keynote Speech and Poster Presentation at Scientific Conferences – Dr. David Gelfand, chief scientific officer, delivered the keynote speech at the Cambridge Healthtech Institute’s Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference and provided an overview of the SmartChip™ Real-Time PCR System. Dr Kumar Kastury, VP of Research, presented a scientific poster on the SmartChip™ Real-Time PCR System at the Cambridge Healthtech Institute’s Ninth Annual Beyond Genome Conference.

”We are very pleased with the progress we have made on all fronts with our SmartChip™ system, a platform that is being designed to perform real time PCR analysis at a throughput of up to 30,000 assays,” stated Alnoor Shivji, WaferGen’s chairman and chief executive officer. “In 2008, we completed alpha testing of our 5,000 assay SmartChip system and now have two beta sites, including our original alpha site partner University of Pittsburgh Medical Center, and are intent on closing on a third beta site in the near future. We believe that the SmartChip System will be the platform of choice for biomarker discovery and validation. We look forward to updating you on our development throughout the year.”

2009 Anticipated Milestones

Present the University of Pittsburgh Medical Center gene expression lung disease results at a scientific conference in the first half of 2009

Release gene expression wound healing results from the University of Texas Southwestern Medical Center in the second half of 2009

Announce a collaboration for the SmartChip™ Real-Time PCR System with a major genomic center in the first half of 2009

Commence an Early Access program providing the 5,000 assay SmartChip™ Real-Time PCR System to limited academic institutions, genome centers, pharmaceutical and biotechnology companies in the second half of 2009

Manufacturing of the SmartChip from Malaysian subsidiary in the second half of 2009

Establish SmartChip sales channel in the second half of 2009

Continued development of additional SmartChip assay panels

About WaferGen

WaferGen Biosystems Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip™ product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. WaferGen currently markets its SmartSlide™ family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide, which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide customers include Harvard University, Mayo Clinic, California Institute of Technology (CalTech), Abbott Labs, and the National Institutes of Health (NIH).

Forward-Looking Statements

This press release contains certain “forward-looking statements”. Such statements include statements relating to the company’s goals, plans and projections, anticipated results of research, performance, reliability and cost-effectiveness of the company’s SmartChip and other systems, and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company’s proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K for the year ended December 31, 2008 filed with the SEC. Investors and security holders are urged to read this document free of charge on the SEC’s web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.